Immunophotonics, Inc. was recently awarded a Small Business Innovative Research (SBIR) Phase I and Phase II Fast-Track grant for research regarding use of the company’s lead drug candidate, IP-001 by the NIH’s National Cancer Institute. This research will be conducted by Immunophotonics Inc and its collaborators at the University of Louisville Division of Surgical Oncology. Read More